Match!
Vincent Chung
City of Hope National Medical Center
CancerPathologyOncologyPancreatic cancerMedicine
130Publications
15H-index
1,103Citations
What is this?
Publications 153
Newest
#1Ramy Sedhom (Johns Hopkins University)H-Index: 1
#2Betty Ferrell (City of Hope National Medical Center)H-Index: 71
Last. Vincent Chung (City of Hope National Medical Center)H-Index: 15
view all 6 authors...
Source
#1Daneng Li (City of Hope National Medical Center)H-Index: 5
#2Can-Lan Sun (City of Hope National Medical Center)H-Index: 18
Last. Simone Fernandes Dos Santos Hughes (City of Hope National Medical Center)
view all 20 authors...
Source
#2Vincent Chung (City of Hope National Medical Center)H-Index: 15
#3Mark T. Hughes (Johns Hopkins University)H-Index: 14
Last. Betty Ferrell (City of Hope National Medical Center)H-Index: 71
view all 9 authors...
Source
#1Andrew Eugene Hendifar (Cedars-Sinai Medical Center)H-Index: 18
#2Edik M. BlaisH-Index: 6
Last. Sameh Mikhail (OSU: Ohio State University)H-Index: 10
view all 17 authors...
Source
#1Paul Frankel (City of Hope National Medical Center)H-Index: 29
#2Vincent Chung (City of Hope National Medical Center)H-Index: 15
Last. Edward M. Newman (City of Hope National Medical Center)H-Index: 20
view all 6 authors...
Abstract Background: There is increasing use of Phase I statistical designs to find a dose that causes rapidly emerging and particularly concerning severe or life-threatening toxicities (dose-limiting toxicities, DLTs) in a specified percent of patients most commonly 25%. While a convenient statistical framework, the foundation for selecting any specified target DLT rate, and its relevance to the recommended Phase II dose is generally lacking. Method: We surveyed 78 medical oncologists, most (69...
Source
#1Paul Frankel (City of Hope National Medical Center)H-Index: 29
#2Vincent Chung (City of Hope National Medical Center)H-Index: 15
Last. Edward M. Newman (City of Hope National Medical Center)H-Index: 20
view all 8 authors...
Importance Phase 1 cancer studies, which guide dose selection for subsequent studies, are almost 3 times more prevalent than phase 3 studies and have a median study duration considerably longer than 2 years, which constitutes a major component of drug development time. Objective To discern a method to reduce the duration of phase 1 studies in adult and pediatric cancer studies without violating risk limits by better accommodating the accrual and evaluation process (or queue). Design The process ...
1 CitationsSource
#1Richard W. KimH-Index: 23
#2Vincent Chung (City of Hope National Medical Center)H-Index: 15
Last. Baek Hui Kim (KU: Korea University)H-Index: 9
view all 11 authors...
Importance Currently, there is no established second-line systemic treatment for biliary tract cancer (BTC). Preclinical data have demonstrated that the presence of tumor-infiltrating CD8 T cells and programmed cell death 1 ligand 1–expressing tumor cells in the tumor microenvironment of BTC supports the rationale of using programmed cell death 1 protein blockade immunotherapy in BTC. Objective To evaluate anticancer activity of nivolumab in patients with advanced refractory BTC. Design, Setting...
Source
#1Betty Ferrell (City of Hope National Medical Center)H-Index: 71
#2Vincent Chung (City of Hope National Medical Center)H-Index: 15
Last. Rhonda S. CooperH-Index: 3
view all 9 authors...
OBJECTIVES: Patients with cancer who are at a transition to Phase I investigational treatments have been identified as an underserved population with regard to palliative care. This disease transition is often accompanied by spiritual and existential concerns. The study objective was to conduct a secondary analysis of data from a larger study testing a palliative care intervention. This paper reports the findings of this secondary focus on the spiritual needs of this population. METHODS: Patient...
Source
#1Michael J. Pishvaian (University of Texas MD Anderson Cancer Center)H-Index: 10
#2Edik M. BlaisH-Index: 6
Last. Davendra Sohal (UC: University of Cincinnati)H-Index: 1
view all 16 authors...
Summary Background About 25% of pancreatic cancers harbour actionable molecular alterations, defined as molecular alterations for which there is clinical or strong preclinical evidence of a predictive benefit from a specific therapy. The Know Your Tumor (KYT) programme includes US patients with pancreatic cancer and enables patients to undergo commercially available multi-omic profiling to provide molecularly tailored therapy options and clinical trial recommendations. We sought to determine whe...
3 CitationsSource
Last. Elana J. FertigH-Index: 22
view all 16 authors...
Source
12345678910